BioMark has recently completed a very encouraging metabolome study that has implication for biomarker signature related to cancer diagnosis. The discovery is being patented.
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement VANCOUVER, BRITISH COLUMBIA
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of
Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2